Cargando…
Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site
As a common intervention among burn patients, skin graft has some risks such as infections and delay of wound healing. The aim of this study was to assess the efficacy and safety of topical 0.25% Timolol Gel (TG) in promoting wound healing in split-thickness skin graft donor sites. We conducted a do...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653643/ https://www.ncbi.nlm.nih.gov/pubmed/34903980 http://dx.doi.org/10.22037/ijpr.2020.114565.14915 |
_version_ | 1784611706273529856 |
---|---|
author | Ghanbarzamani, Amirhossein Salehifar, Ebrahim Jafarirad, Abdolreza Hesamirostami, Mohammad Hossein Bagherzadehsaba, Ali Saeedi, Majid Ghazaeian, Monireh Khorasani, Ghasemali Moosazadeh, Mahmood |
author_facet | Ghanbarzamani, Amirhossein Salehifar, Ebrahim Jafarirad, Abdolreza Hesamirostami, Mohammad Hossein Bagherzadehsaba, Ali Saeedi, Majid Ghazaeian, Monireh Khorasani, Ghasemali Moosazadeh, Mahmood |
author_sort | Ghanbarzamani, Amirhossein |
collection | PubMed |
description | As a common intervention among burn patients, skin graft has some risks such as infections and delay of wound healing. The aim of this study was to assess the efficacy and safety of topical 0.25% Timolol Gel (TG) in promoting wound healing in split-thickness skin graft donor sites. We conducted a double-blind, randomized clinical trial to assess re-epithelialization time, the level of pain based on the Visual Analog Scale (VAS), and the wound infection incidence. The scar status was also evaluated by the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). Totally, 64 patients were randomly assigned to the study groups. The two groups showed a significant difference in healing time (14.5 ± 3.2 vs. 11.5 ± 2.3 days, P < 0.001). No infection occurred in either group, and 3 cases of transplant rejection were observed in the placebo group. The VAS was significantly different on days 1, 2, 3, 4, and 7 (P < 0.05). In the third month, the results showed a significant difference in terms of VSS (P = 0.005). Topical TG, due to its favorable effects on wound healing and pain reduction, can be administered as a therapeutic agent in patients with a skin graft. |
format | Online Article Text |
id | pubmed-8653643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Shaheed Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-86536432021-12-12 Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site Ghanbarzamani, Amirhossein Salehifar, Ebrahim Jafarirad, Abdolreza Hesamirostami, Mohammad Hossein Bagherzadehsaba, Ali Saeedi, Majid Ghazaeian, Monireh Khorasani, Ghasemali Moosazadeh, Mahmood Iran J Pharm Res Original Article As a common intervention among burn patients, skin graft has some risks such as infections and delay of wound healing. The aim of this study was to assess the efficacy and safety of topical 0.25% Timolol Gel (TG) in promoting wound healing in split-thickness skin graft donor sites. We conducted a double-blind, randomized clinical trial to assess re-epithelialization time, the level of pain based on the Visual Analog Scale (VAS), and the wound infection incidence. The scar status was also evaluated by the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). Totally, 64 patients were randomly assigned to the study groups. The two groups showed a significant difference in healing time (14.5 ± 3.2 vs. 11.5 ± 2.3 days, P < 0.001). No infection occurred in either group, and 3 cases of transplant rejection were observed in the placebo group. The VAS was significantly different on days 1, 2, 3, 4, and 7 (P < 0.05). In the third month, the results showed a significant difference in terms of VSS (P = 0.005). Topical TG, due to its favorable effects on wound healing and pain reduction, can be administered as a therapeutic agent in patients with a skin graft. Shaheed Beheshti University of Medical Sciences 2021 /pmc/articles/PMC8653643/ /pubmed/34903980 http://dx.doi.org/10.22037/ijpr.2020.114565.14915 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ghanbarzamani, Amirhossein Salehifar, Ebrahim Jafarirad, Abdolreza Hesamirostami, Mohammad Hossein Bagherzadehsaba, Ali Saeedi, Majid Ghazaeian, Monireh Khorasani, Ghasemali Moosazadeh, Mahmood Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site |
title | Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site |
title_full | Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site |
title_fullStr | Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site |
title_full_unstemmed | Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site |
title_short | Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site |
title_sort | efficacy and safety of 0.25% timolol gel in healing split-thickness skin graft site |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653643/ https://www.ncbi.nlm.nih.gov/pubmed/34903980 http://dx.doi.org/10.22037/ijpr.2020.114565.14915 |
work_keys_str_mv | AT ghanbarzamaniamirhossein efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT salehifarebrahim efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT jafariradabdolreza efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT hesamirostamimohammadhossein efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT bagherzadehsabaali efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT saeedimajid efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT ghazaeianmonireh efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT khorasanighasemali efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite AT moosazadehmahmood efficacyandsafetyof025timololgelinhealingsplitthicknessskingraftsite |